Relative to vaccine and pharmaceutical products purchased, promoted, or distributed by the state and its political subdivisions.
Impact
One significant consequence of SB319 is its explicit non-application to the annual flu vaccine and circumstances when a state of emergency is declared by the governor. The latter provision ensures that during emergencies, the flexibility to mandate vaccinations is retained by the state. The bill modifies existing statutory duties of the Department of Health and Human Services (DHHS), reinforcing their responsibility to safeguard public health while adhering to the revised regulations on pharmaceutical products.
Summary
Senate Bill 319 (SB319) establishes specific regulations regarding the purchase, promotion, or distribution of vaccines and pharmaceutical products by the state of New Hampshire and its political subdivisions. Under this bill, these entities are prohibited from engaging with any vaccine or pharmaceutical product that has not undergone voluntary human clinical trials. The intent of this legislation is to ensure that only rigorously tested medical products are utilized in state-sponsored programs, thereby aiming to protect public health and bolster consumer confidence in vaccination initiatives.
Contention
Discussions surrounding SB319 may center on the implications of preemptively restricting certain vaccines, particularly those developed rapidly during public health emergencies, such as the COVID-19 pandemic. Critics may argue that this bill could lead to increased public health risks by limiting access to timely vaccinations during urgent health situations. Detractors may further contend that the bill's tight constraints could undermine efforts to maintain high vaccination rates within the population, especially for preventable diseases.
Financial_implications
SB319 anticipates significant fiscal impacts on state expenditures, particularly with respect to purchasing vaccines. The bill is projected to reduce state expenditures cumulatively by millions in subsequent fiscal years. The Department of Health and Human Services estimates that adhering to the provisions of this bill could avert costs associated with COVID-19 vaccinations, although it acknowledges the possibility of increased Medicaid and healthcare costs stemming from a rise in COVID-19 cases if vaccination rates decline.